News

Deal Announcements

Aragon Pharma Raises $22 Million Series B

Monday, April 26, 2010 5:36:00 AM PDT | VentureDeal Staff
San Diego, California  --  In its second institutional venture capital funding round, Aragon Pharmaceuticals raised $22 million.

Aragon is developing selective androgen receptor degraders and selective estrogen receptor degrade as for the treatment of prostate and breast cancers.

Aisling Capital led the round, which also included The Column Group and OrbiMed.  The company said it would use the funding proceeds to advance its lead candidates into clinical trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1